This company has been marked as potentially delisted and may not be actively trading. Amryt Pharma (AMYT) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock AMYT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Alembic Pharmaceuticals Ltd.October 13, 2023 | wsj.comAMYT Historical DataOctober 9, 2023 | investing.comBeijing Sun-Novo Pharmaceutical Research Co. Ltd. AJuly 28, 2023 | wsj.comAmryt Pharma (Nasdaq:AMYT) HeadlineTrading was temporarily halted for "AMYT" at 07:04 PM with a stated reason of "News pending."...April 12, 2023 | marketbeat.com2022 for Chiesi: The Group’s international growth continuesApril 11, 2023 | finance.yahoo.comHigh Court of Justice of England and Wales Sanctions Scheme of ArrangementApril 3, 2023 | finance.yahoo.comClear Harbor Asset Management LLC Sells 13,573 Shares of Amryt Pharma plc (NASDAQ:AMYT)March 30, 2023 | marketbeat.comAmryt Pharma Stock (NASDAQ:AMYT), DividendsMarch 16, 2023 | benzinga.comAmryt Pharma plc (NASDAQ:AMYT) Sees Significant Decline in Short InterestMarch 6, 2023 | marketbeat.comArmistice Capital LLC Purchases 94,000 Shares of Amryt Pharma plc (NASDAQ:AMYT)February 24, 2023 | marketbeat.comAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023February 16, 2023 | finance.yahoo.comAmryt Pharma Sees Unusually High Options Volume (NASDAQ:AMYT)January 13, 2023 | marketbeat.comAmryt Pharma (NASDAQ:AMYT) Receives Hold Rating from Canaccord Genuity GroupJanuary 10, 2023 | marketbeat.comAmryt Pharma's (AMYT) "Market Perform" Rating Reaffirmed at SVB LeerinkJanuary 9, 2023 | marketbeat.comWhy CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving PremarketJanuary 9, 2023 | msn.comEuropean drugmakers including AstraZeneca pony up for U.S.-listed biopharmasJanuary 9, 2023 | msn.comMaxim Group Reaffirms Their Buy Rating on Amryt Pharma (AMYT)January 6, 2023 | markets.businessinsider.comAmryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFHJanuary 5, 2023 | finance.yahoo.comAmryt Pharma plc (NASDAQ:AMYT) Sees Significant Decrease in Short InterestDecember 16, 2022 | marketbeat.comShort Interest in Amryt Pharma plc (NASDAQ:AMYT) Decreases By 15.2%Short Interest in Amryt Pharma plc (NASDAQ:AMYT) Decreases By 15.2%...December 2, 2022 | marketbeat.comAmryt Pharma plc (NASDAQ:AMYT) Sees Significant Growth in Short InterestNovember 13, 2022 | marketbeat.comSVB Securities Keeps Their Buy Rating on Amryt Pharma (AMYT)November 7, 2022 | markets.businessinsider.comAmryt Pharma PLC (AMYT) Q3 2022 Earnings Call TranscriptNovember 6, 2022 | seekingalpha.comAmryt Reports Q3 2022 Financial and Operational ResultsNovember 3, 2022 | finance.yahoo.comLigand Pharmaceuticals (LGND) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 31, 2022 | msn.comAmryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 27, 2022 | finance.yahoo.comQ3 2022 EPS Estimates for Amryt Pharma plc Reduced by SVB Leerink (NASDAQ:AMYT)October 27, 2022 | marketbeat.comAmryt Pharma (AMYT) Set to Announce Quarterly Earnings on ThursdayOctober 27, 2022 | marketbeat.comThe British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis BullosaOctober 25, 2022 | finance.yahoo.comAmryt Supports Global EB Awareness Week 2022October 24, 2022 | finance.yahoo.comAmryt to Report Q3 2022 Results on November 3, 2022October 19, 2022 | finance.yahoo.comShort Interest in Amryt Pharma plc (NASDAQ:AMYT) Rises By 17.0%October 16, 2022 | marketbeat.comShort Interest in Amryt Pharma plc (NASDAQ:AMYT) Decreases By 16.9%September 30, 2022 | marketbeat.comAmryt Supports FH Awareness Day – September 24, 2022September 23, 2022 | finance.yahoo.comAmryt Pharma Gets CHMP Backing for Mycapssa in Acromegaly >AMYTSeptember 16, 2022 | marketwatch.comCHMP adopts positive opinion for Mycapssa® for the treatment of AcromegalySeptember 16, 2022 | finance.yahoo.comAmryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder CandidateSeptember 8, 2022 | msn.comAmryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great BritainSeptember 8, 2022 | finance.yahoo.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022September 7, 2022 | finance.yahoo.comAmryt Pharma's (AMYT) Buy Rating Reiterated at Canaccord Genuity GroupSeptember 6, 2022 | marketbeat.comAmryt Pharma (NASDAQ:AMYT) Rating Reiterated by HC WainwrightAugust 10, 2022 | marketbeat.comCan Amryt Pharma PLC Sponsored ADR (AMYT) Climb 187% to Reach the Level Wall Street Analysts Expect?August 9, 2022 | finance.yahoo.comAmryt Reports Record Q2 2022 ResultsAugust 4, 2022 | finance.yahoo.comShort Interest in Amryt Pharma plc (NASDAQ:AMYT) Increases By 24.6%August 2, 2022 | marketbeat.comAmryt to Report Q2 2022 Results on August 4, 2022July 21, 2022 | finance.yahoo.comAmryt Shares Shoot Higher As FDA Grants Orphan Drug Status To Carcinoid Tumor CandidateJuly 14, 2022 | markets.businessinsider.comAmryt Gets FDA Orphan Designation for Mycapssa in Carcinoid Syndrome >AMYTJuly 14, 2022 | marketwatch.comAmryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid SyndromeJuly 14, 2022 | finance.yahoo.comAmryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022July 7, 2022 | finance.yahoo.comAmryt Announces Appointment of Dr Tracy Cunningham as Chief Medical OfficerJune 27, 2022 | finance.yahoo.com Get Amryt Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMYT Media Mentions By Week AMYT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMYT News Sentiment▼0.001.04▲Average Medical News Sentiment AMYT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMYT Articles This Week▼00▲AMYT Articles Average Week Get the Latest News and Ratings for AMYT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Amryt Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies MOR News CALT News ZYME News MBX News AVTE News CYBN News VIRI News OSTX News ELYM News ATNM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMYT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amryt Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access